Not recruiting

Study on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18-75 with Dyslipidemia

Verified siteInvestigational

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called AZD0780 on a condition known as dyslipidemia. Dyslipidemia is a medical condition where there are abnormal levels of lipids, such as cholesterol, in the blood. A common form of dyslipidemia is high levels of low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol, which can increase the risk of cardiovascular diseases like heart disease and stroke.

The purpose of this study is to evaluate how different doses of AZD0780 affect LDL-C levels compared to a placebo. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will last for a period of 12 weeks, during which the safety and tolerability of AZD0780 will also be assessed. This means that researchers will monitor any side effects or health changes in participants to ensure the treatment is safe.

Throughout the study, participants will take the medication in the form of a film-coated tablet, which is taken orally. The study aims to provide valuable information on how AZD0780 can help manage cholesterol levels in people with dyslipidemia, potentially offering a new treatment option for those at risk of cardiovascular diseases.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial visit
Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria, such as age and cholesterol levels.
You will be asked to provide a fasting blood sample to measure your low-density lipoprotein cholesterol (LDL-C) and triglycerides. Your current medication regimen will be reviewed to ensure no changes are planned during the study.
Step 2
Randomization
After confirming eligibility, you will be randomly assigned to one of the study groups. This means you may receive either the study medication AZD0780 or a placebo, which looks like the medication but does not contain the active ingredient.
The study is double-blind, meaning neither you nor the study staff will know which group you are in.
Step 3
Medication administration
You will take the assigned medication orally in the form of a film-coated tablet. The dosage and frequency will be determined by the study protocol, and you will be instructed on how to take the medication correctly.
The duration of medication administration is planned for 12 weeks.
Step 4
Follow-up visits
Throughout the study, you will attend regular follow-up visits. These visits are scheduled to monitor your health and the effects of the medication.
During these visits, blood samples will be taken to measure changes in your cholesterol levels and other health markers. Your vital signs and overall health will also be assessed.
Step 5
Final assessment
At the end of the 12-week period, you will have a final assessment. This will include a comprehensive evaluation of your cholesterol levels and any changes from the start of the study.
The study team will review any side effects or adverse events you may have experienced during the trial.

Who can join the trial?

6 criteria

Men and women who cannot have children, aged 18 to 75 years old.
Participants must have a fasting low-density lipoprotein cholesterol (LDL-C) level between 70 mg/dL (1.8 mmol/L) and 190 mg/dL (4.9 mmol/L) at the start of the study. LDL-C is often called "bad cholesterol" because high levels can lead to heart disease.
Participants must have fasting triglycerides less than 400 mg/dL (4.52 mmol/L) at the start of the study. Triglycerides are a type of fat found in your blood.
Participants should have been taking moderate or high-intensity statin therapy for at least 2 months before the study starts. Statin therapy involves medications that help lower cholesterol levels in the blood.
There should be no planned changes in medication or dosage during the study.
Participants must have a body mass index (BMI) of 19.0 kg/m² or higher. BMI is a measure of body fat based on height and weight.

Who cannot join the trial?

10 criteria

Patients with any serious medical condition that might interfere with the study.
Patients who are pregnant or breastfeeding.
Patients who have participated in another clinical trial within the last 30 days.
Patients with a history of allergic reactions to the study medication.
Patients with uncontrolled high blood pressure.
Patients with severe liver or kidney disease.
Patients with a history of drug or alcohol abuse.
Patients who are unable to follow the study procedures.
Patients with a history of heart disease, such as a heart attack or stroke.
Patients taking medications that might interfere with the study drug.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Aarhus University Hospital
Verified
Aarhus, Denmark
Hospital De La Santa Creu I Sant Pau
Verified
Barcelona, Spain
Region Midtjylland
Responsive
Aarhus, Denmark

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AZD0780 is a medication being studied for its potential to help people with dyslipidemia, a condition where there are unhealthy levels of lipids, like cholesterol, in the blood. This medication is being tested to see if it can lower the levels of bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), which is often linked to heart disease. The study aims to find out how effective and safe AZD0780 is for patients, and whether it can be a good option for managing cholesterol levels without causing significant side effects.

1-[6-[[(1S,3S)-3-[[5-(Difluoromethoxy)Pyrimidin-2-Yl]Amino]Cyclopentyl]Amino]Pyridin-3-Yl]Pyridin-2-One

What is already known about the treatment

AZD0780 – AZD0780 is administered orally in the form of a tablet and is currently being studied in clinical trials for its potential to treat dyslipidemia, a condition characterized by abnormal levels of lipids in the blood, which can lead to cardiovascular diseases. The medication is in the experimental phase and is not yet widely recognized in medical literature as a standard treatment. It is primarily aimed at reducing low-density lipoprotein cholesterol (LDL-C), which is often referred to as "bad cholesterol" due to its association with heart disease. AZD0780 works by targeting specific pathways in the body to lower LDL-C levels, although the exact molecular mechanism is still under investigation. It falls under the pharmacological classification of lipid-lowering agents.

Investigated diseases

Dyslipidemia – Dyslipidemia refers to an abnormal amount of lipids in the blood. It often involves high levels of low-density lipoprotein cholesterol (LDL-C), which is commonly known as "bad" cholesterol. This condition can lead to the buildup of cholesterol in the arteries, increasing the risk of cardiovascular diseases. Over time, the accumulation of cholesterol can cause narrowing and hardening of the arteries, a process known as atherosclerosis. Dyslipidemia can also involve low levels of high-density lipoprotein cholesterol (HDL-C) or high levels of triglycerides. These lipid imbalances can contribute to the development of heart disease and stroke.